현재 위치
Home
Original Article
Molsidomine, Nicorandil, Trimetazidine의 안전성 관련 체계적 고찰
A Systematic Review on Drug Safety for Molsidomine, Nicorandil and Trimetazidine
-
- 발행기관
- 한국임상약학회 바로가기
-
- 간행물
- 한국임상약학회지 KCI 등재 바로가기
-
- 통권
- 제26권 제2호 (2016.06)바로가기
-
- 페이지
- pp.172-180
-
- 저자
-
- 언어
- 한국어(KOR)
-
- URL
- https://www.earticle.net/Article/A278906
※ 기관로그인 시 무료 이용이 가능합니다.
4,000원
원문정보
초록
- 영어
- Background: Ischemic heart disease is the most common type of heart disease and an important cause of death in Korea. Among marketed anti-anginal medications, molsidomine, nicorandil, and trimetazidine are approved in Korea with unique mechanism of actions. As these drugs are not approved by the US Food and Drug Administration, the access to the up-to-dated and comprehensive safety-related information has been less than optimal from drug information resources used by Korean pharmacists. Methods: A systematic review was conducted using Embase and Korean manuscripts to compile safety updates for these medications. Out of 418 articles from keyword searches, 52 studies were reviewed in full to compare adverse effects (AEs) with the approved package inserts (PI). Results: Molsidomine related adverse effects were mostly mild or moderate, but anxiety, palpitation, epigastric pain, and sexual potency reduction were additional AEs found from the review not listed in PI. Although PI has included ulceration in oral cavity and gastrointestinal tracts including anus by nicorandil, the Korea FDA recently recommended adding corneal, genital, and skin ulcers to the approved PI. Trimetazidine induced Parkinsonism, worsening of the symptoms for patients diagnosed with Parkinson's disease, gastrointestinal burning, and muscle cramps were additionally identified AEs not listed in PI for trimetazidine. Conclusion: Continuous evaluations of the safety profile of these agents are needed to balance the risks and benefits to provide evidence-based safety counseling to the patients. In addition, more focused efforts on spontaneous reporting are warranted by healthcare professionals to safeguard patients against AEs.
목차
ABSTRACT
연구 방법
연구 결과 및 고찰
결론
참고문헌
키워드
Molsidomine nicorandil trimetazidine safety adverse effects저자
간행물 정보
발행기관
-
- 발행기관명
- 한국임상약학회 [Korean College of Clinical Pharmacy]
- 설립연도
- 1
- 분야
- 의약학>약학
- 소개
- 합리적 약물치료(rational pharmacotherapy)의 보장 및 증진을 궁극목적으로 하며 이를 달성하기 위해 임상약학의 발전과 회원 상호간의 친목을 도모한다.
간행물
-
- 간행물명
- 한국임상약학회지 [Korean Journal of Clinical Pharmacy]
- 간기
- 계간
- pISSN
- 1226-6051
- 수록기간
- 1991~2026
- 등재여부
- KCI 등재
- 십진분류
- KDC 518 DDC 615
이 권호 내 다른 논문 / 한국임상약학회지 제26권 제2호
피인용수 : 0건 (자료제공 : 네이버학술정보)
함께 이용한 논문 이 논문을 다운로드한 분들이 이용한 다른 논문입니다.
출처 : 네이버학술정보
0개의 논문이 장바구니에 담겼습니다.